After a quarter of century of rapid technological advances, research has revealed the complexity of cancer, a disease intimately related to the dynamic transformation of the genome. However, the full understanding of the molecular onset of this disease is still far from achieved and the search for mechanisms of treatment will follow closely. It is here that Nanotechnology enters the fray offering a wealth of tools to diagnose and treat cancer. In fact, the National Cancer Institute predicts that over the next years, nanotechnology will result in important advances in early detection, molecular imaging, targeted and multifunctional therapeutics, prevention and control of cancer. Nanotechnology offers numerous tools to diagnose and treat cancer, such as new imaging agents, multifunctional devices capable of overcome biological barriers to deliver therapeutic agents directly to cells and tissues involved in cancer growth and metastasis, and devices capable of predicting molecular changes to prevent action against precancerous cells. Nanomaterials-based delivery systems in Theranostics (Diagnostics & Therapy) provide better penetration of therapeutic and diagnostic substances within the body at a reduced risk in comparison to conventional therapies. At the present time, there is a growing need to enhance the capability of theranostics procedures where nanomaterials-based sensors may provide for the simultaneous detection of several gene-associated conditions and nanodevices with the ability to monitor real-time drug action. These innovative multifunctional nanocarriers for cancer theranostics may allow the development of diagnostics systems such as colorimetric and immunoassays, and in therapy approaches through gene therapy, drug delivery and tumor targeting systems in cancer. Some of the thousands and thousands of published nanosystems so far will most likely revolutionize our understanding of biological mechanisms and push forward the clinical practice through their integration in future diagnostics platforms. Nevertheless, despite the significant efforts towards the use of nanomaterials in biologically relevant research, more in vivo studies are needed to assess the applicability of these materials as delivery agents. In fact, only a few went through feasible clinical trials. Nanomaterials have to serve as the norm rather than an exception in the future conventional cancer treatments. Future in vivo work will need to carefully consider the correct choice of chemical modifications to incorporate into the multifunctional nanocarriers to avoid activation off-target, side effects and toxicity. Moreover the majority of studies on nanomaterials do not consider the final application to guide the design of nanomaterial. Instead, the focus is predominantly on engineering materials with specific physical or chemical properties. It is imperative to learn how advances in nanosystem’s capabilities are being used to identify new diagnostic and therapy tools driving the development of personalized medicine in oncology; discover how integrating cancer research and nanotechnology modeling can help patient diagnosis and treatment; recognize how to translate nanotheranostics data into an actionable clinical strategy; discuss with industry leaders how nanotheranostics is evolving and what the impact is on current research efforts; and last but not least, learn what approaches are proving fruitful in turning promising clinical data into treatment realities.

Applications of Targeted Nano-Drugs and Delivery Systems: Nanoscience and Nanotechnology in Drug Delivery explores the applications of Nano-drugs and their delivery systems, investigating the role they can play in key body systems and major diseases. The book explores how nanotechnology can be deployed in developing new drug delivery systems and how they enable pharmaceutical companies to reformulate existing drugs on the market, thereby extending the lifetime of products and enhancing performance by increasing effectiveness, safety and patient adherence, and ultimately reducing healthcare cost. Reflecting the interdisciplinary nature of the subject matter, this book includes contributions by experts from different fields. Readers will find a reference and practical source of guidance for researchers, students and scientists working in the fields of nanotechnology, materials science, and technology and biomedical science. - Enables readers from different fields to access recent research and protocols across traditional boundaries - Focuses on protocols and techniques, as well as the knowledge base of the field, thus enabling those in R&D to learn about, and successfully deploy, cutting-edge techniques - Explores the applications of Nano-drugs and their delivery systems, investigating the role they can play in key body systems and major disease types

Cancer Nanotheranostics, Volume 2 continues the discussion of the important work being done in this field of cancer nanotechnology. The contents of these two volumes are explained in detail as follows. In the first volume of Cancer Nanotheranostics, we discuss the role of different nanomaterials for cancer therapy including lipid-based nanomaterials, protein and peptide-based nanomaterials, polymer-based nanomaterials, metal-organic nanomaterials, porphyrin-based nanomaterials, metal-based nanomaterials, silica-based nanomaterials, exosome-based nanomaterials, and nano-antibodies. This important second volume discusses nano-based diagnosis of cancer, nano-oncology for clinical applications, nano-immunotherapy, nano-based photothermal cancer therapy, nanoerythrosomes for cancer drug delivery, regulatory perspectives of nanomaterials, limitations of cancer nanotheranostics, safety of nanobiomaterials for cancer nanotheranostics, multifunctional nanomaterials for targeting cancer nanotheranostics, and the role of artificial intelligence in cancer nanotheranostics. Volume 2 is a vital continuation of this two-volume set. Together, these two volumes create a comprehensive and unique examination of this important area of research.

This book is specifically designed to provide information about various nanocarriers currently developed under the emerging field of nanotheranostics for a sustained, controlled, and targeted co-delivery of diagnostic and therapeutic agents. Diverse theranostic applications of nanotechnology and their limitations are also addressed. It integrates nanobiotechnology with theranostic applications. The combined term nanotheranostics has diverse application particularly in chemotherapy and other infectious diseases.Among other topics addressed are antimicrobial resistance, targeting intra-cellular pathogens, viruses and bacteria, chemotherapy, cancer therapeutics, and inflammatory disorders. This interdisciplinary volume is essential for a diverse group of readers including nanotechnologists, microbiologists, biotechnologists, bioengineering and bioprocess industry.

Nanotheranostics is a recent medical field which integrates diagnostic imaging protocols and therapeutic functions to monitor real time drug release in the body and distribution to the target site. The combined processes allow technicians to observe the effectiveness of a specifically designed drug candidate and predict its possible side effects. All these features help clinicians in optimizing treatment options for cancer and other diseases for the individual patient. Current research is tailored to individual therapy because each drug may display a variety of responses depending on variations in an individual’s genetics and subsequently, their clinical biochemistry. Many tumors are still challenging for therapists in terms of available treatment and nanotheranostic strategies may help them to combat cancer more efficiently. Advances in Cancer Nanotheranostics for Experimental and Personalized Medicine presents information about current theranostic technologies in use at clinics and recent research on nanotheranostic applications, with a focus on cancer treatment. Information is presented in seven organized chapters that cover the basics of cancer nanotheranostics, tumor microenvironmental factors, gene therapy and gene delivery concepts, and the combined application of diagnostic imaging with cancer chemotherapy. A chapter focusing on the role of non-coding MRNAs in breast cancer carcinogenesis is also included, giving readers a glimpse of the complexities in the molecular biology of cancer which drive the need for new theranostic technologies. The book is of interest to medical professionals (including oncologists and specialists in internal medicine), diagnostic imaging technicians, and researchers in the fields of pharmacology, molecular biology and nuclear medicine.

The Charnolosome as a Novel Nanothereranostic Biomarker: Overcoming Future Challenges in Medicine provides an overview of the charnolosome and its potential as a biomarker of cell injury. Based on the author's original discovery of the charnoly body in the developing, undernourished rat cerebellar Purkinje neurons, this book delves into the potential for utilizing this mitochondria and lysosomal-derived intracellular organelle as a nanotheranostic biomarker to prevent and cure various diseases. The book discusses the cellular, molecular, genetic, and epigenetic mechanisms of charnolosomes and charnolosome-derived nano-vesicles. It also investigates the molecular mechanisms underlying auto-inflammatory, autoimmune, and infectious diseases resulting from their compromised mitochondrial bioenergetics, and the potential use of the charnolosome in preventing and curing such conditions. - Shares the latest knowledge on the charnolosome and charnolosome-derived nano-vesicles and their significance at a cellular and molecular level - Considers the charnolosome in relation to a range of conditions, including neurodegenerative, metabolic, and multi-drug resistant systemic diseases - Presents future perspectives of the charnolosome in personalized nanotheranostics

This book is the first to focus specifically on cancer nanotheranostics. Each of the chapters that make up this comprehensive volume is authored by a researcher, clinician, or regulatory agency member known for their expertise in this field. Theranostics, the technology to simultaneously diagnose and treat a disease, is a nascent field that is growing rapidly in this era of personalized medicine. As the need for cost-effective disease diagnosis grows, drug delivery systems that can act as multifunctional carriers for imaging contrast and therapy agents could provide unique breakthroughs in oncology. Nanotechnology has enabled the development of smart theranostic platforms that can concurrently diagnose disease, start primary treatment, monitor response and initiate secondary treatments if required. In oncology, chemotherapeutics have been routinely used. Some drugs have proven effective but all carry risks of adverse side effects. There is growing interest in using remotely triggered drug delivery systems to limit cytotoxicity in the diseased area. This book reviews the use of theranostic nanoparticles for cancer applications over the past decade. First, it briefly discusses the challenges and limitations of conventional cancer treatments, and presents an overview of the use of nanotechnology in treating cancer. These introductory chapters are followed by those exploring cancer diagnosis and a myriad of delivery methods for nanotherapeutics. The book also addresses multifunctional platforms, treatment monitoring, and regulatory considerations. As a whole, the book aims to briefly summarize the development and clinical potential of various nanotheranostics for cancer applications, and to delineate the challenges that must be overcome for successful clinical development and implementation of such cancer theranostics.

Nucleic Acid Nanotheranostics: Biomedical Applications offers a comprehensive overview of improvements and new trends in fabrication of nanostructures as theranostic multifunctional carriers in gene therapy. With a strong focus on medical applications (comprising diagnosis, therapy and imaging), the book also examines gene therapy in an individual patient's cells or tissues to treat genetic diseases. Sections cover Biomedical and Diagnostic applications of Nucleic Acids, Biologic and Synthetic Advanced Nanostructures for nucleic acid delivery, and important considerations of nanomedicine. This book is a valuable guide for materials scientists, physicians, chemists and engineers, but is also ideal for clinicians wishing to expand their knowledge. - Provides a unique source of knowledge (theoretical as well as practical) on nanotheranostic materials for gene therapy at all levels and related scientific areas - Covers the pros and cons related to viral and nanomaterial-based delivery of nucleic acids in terms of biosafety, carrier selection, synthesis and bioimaging - Presents the only book to include an analysis of nanoformulations approved for clinical use

Nanomedicine is evolving with novel drug formulations devised for multifunctional approaches towards diagnostics ad therapeutics. Nanomedicine-based drug therapy is normally explored at a fixed dose. The drug action is time-dependent, dose-dependent and patient-specific. To overcome challenges of nanomedicine testing, artificial intelligence (AI) serves as a helping tool for optimizing the drug and dose parameters. Real time conversions between these two features enables upgradation of patient data acquisition and improved design of nanomaterials. In this scenario, AI-based pattern analysis and algorithms models can greatly improve accuracy of diagnostics and therapeutics. This book gives a comprehensive explanation of the role of machine learning and artificial intelligence in cancer nanomedicine. It presents 10 chapters that cover multiple dimensions of the subject. These dimensions are: - The need of AI and ML in designing new cancer drugs - Application of AI in cancer drug design - AI-based drug delivery models for cancer drugs - Diagnostic applications of AI - Intelligent nanosensors for biomarker profiling - Predictive models for metastatic cancer - Cancer nanotheranostics - Ethics of AI in medicine Contributions have been made by 16 researchers who are experts in pharmacology and drug design. The contents of the book bridge knowledge gaps between the fields of biomedical engineering, pharmacology and clinical medicine, with a focus on cancer treatment. The book serves as a reference for scholars learning about cancer diagnostics and therapeutics. Biomedical engineers who are involved in healthcare projects will also find the concepts and techniques highlighted in the book informative for understanding modern computer-based approaches used to solve clinical problems.

This book presents nanomaterials for cancer detection using a variety of state-of-the-art imaging techniques. Clinical applications are also highlighted. The unique size-dependent properties and convenient surfaces for molecular assembly make these nanomaterials essential for a variety of innovative imaging techniques. This book covers important imaging modalities, synthesis of nanoparticles with specific functional properties, and clinical applications including the development of anticancer drugs. The information presented here involves contributions from chemistry, materials science, materials characterization, cell engineering, and clinical testing. The book will be essential reading to experienced clinicians as well as a wide range of scholars and researchers interested in nanotechnology and imaging techniques for cancer detection.